Developer docs
API playgroundTry for free, no card

Search company profiles

Kate Therapeutics

Full company profile

uuid0000hes

Namestring
Kate Therapeutics
Legal namestring
Kate Therapeutics Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Kate Therapeutics was a privately held biotechnology company headquartered in San Diego, California, that developed next-generation gene therapies targeting skeletal muscle and heart diseases. Founded circa 2020, the company emerged from stealth mode in June 2023 alongside a $51 million Series A financing led by Versant Ventures and Westlake Village BioPartners, with participation from OUP (Osage University Partners) and UF Innovate Ventures. It was subsequently acquired by Novartis in 2024 for approximately $1.1 billion.

The company's core technology centered on a proprietary MyoAAV capsid platform combined with novel gene therapy cargo technologies, enabling targeted delivery of therapeutic genes to muscle and cardiac tissues. The MyoAAV capsid was reported to achieve comparable or improved muscle targeting at approximately 100-fold lower doses than earlier gene therapy approaches (specifically AT132), directly addressing the liver toxicity issues that had derailed earlier neuromuscular gene therapy programs. The disclosed pipeline included KT430 for X-linked myotubular myopathy (XLMTM), which was exclusively licensed to Astellas Pharma and advanced as ASP2957 into the Phase I/II VALOR trial, plus preclinical programs targeting myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.

The business model was that of a research-stage biotech: Kate generated no product revenue and monetized through scientific publications, conference presence, and strategic licensing partnerships rather than direct commercialization. Following its acquisition, Kate's programs and expertise were integrated into Novartis's consolidated genetic medicine research operations in San Diego, joining prior acquisitions including AveXis and DTx Pharma. The founders included Sharif Tabebordbar (Chief Scientific Officer), Kevin Forrest (Chief Executive Officer), and Mark Fielden (SVP of Nonclinical Development), with Beth Seidenberg serving as Chair of the Board.

Short descriptiontext

Kate Therapeutics was a San Diego-based biotechnology company that developed next-generation gene therapies for muscle and heart diseases using its proprietary MyoAAV capsid platform; the company was acquired by Novartis in 2024 for approximately $1.1 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gene therapy development, muscle disease therapeutics, cardiac disease treatments, viral vector capsids, rare disease biotech
Industry4 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Gene Therapy - Rare Neuromuscular & Cardiac Diseases
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kate Therapeutics developed next-generation gene therapies for muscle and heart diseases, built on a proprietary capsid and cargo delivery platform. Its lead asset, KT430, targeted X-linked myotubular myopathy (XLMTM) and was licensed exclusively to Astellas Pharma (incorporated into ASP2957), while additional pipeline programs addressed myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. The company's MyoAAV capsid technology enabled targeted muscle delivery at approximately 100-fold lower doses than earlier gene therapy approaches, addressing liver toxicity concerns that had hindered prior programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • MyoAAV3.8 demonstrated approximately 100-fold lower dosing requirement than AT132 while maintaining improved muscle targeting in preclinical studies
Product overview1 text field

Kate Therapeutics was a gene therapy company focused on developing targeted delivery platforms for muscle and heart diseases. The company built its business around a novel capsid and cargo technology platform, including the proprietary MyoAAV capsid technology that enables improved muscle targeting. The pipeline included KT430 (licensed to Astellas for X-linked myotubular myopathy) and programs targeting myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. Kate Therapeutics was acquired by Novartis in 2024 for approximately $1.1 billion.

Product and service1 record
1Novel Capsid and Cargo Technology Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Novartis acquired Kate Therapeutics in 2024 for $1.1 billion as part of its strategy to build a leading gene therapy capability. Kate's programs and expertise in neuromuscular diseases were integrated into Novartis's consolidated genetic medicine research operations in San Diego, combining with AveXis, DTx Pharma, and other acquisitions under Executive Director Bryan Laffitte.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-06-08
Description

Kate Therapeutics granted Astellas Pharma Inc. an exclusive license to develop KT430 (later incorporated into ASP2957) for X-linked myotubular myopathy (XLMTM). Astellas advanced this therapy into Phase I/II VALOR trial using the MyoAAV capsid technology from Kate. The partnership represents a significant licensing arrangement for muscle disease gene therapies.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gene therapy company with AAV-based platform and clinical programs in rare neuromuscular and metabolic diseases. Comparable as a developer of AAV-delivered gene therapies for rare genetic disorders.

TypeEmerging player
Description

Clinical-stage AAV gene therapy company focused on cardiac and neuromuscular diseases. Comparable to Kate in combining cardiac and muscle targets with AAV delivery technology.

TypeDirect peer
Description

Clinical-stage gene therapy company with proprietary AAV capsid platform (NAV Technology) used across multiple partners for neuromuscular and rare disease indications. Comparable to Kate's MyoAAV capsid platform approach.

TypeEmerging player
Description

Clinical-stage gene therapy company developing treatments for genetic heart disease, including cardiomyopathy. Comparable to Kate's cardiac gene therapy component and rare disease focus.

TypeBroad incumbent
Description

Large rare disease biopharmaceutical company developing AAV gene therapies (e.g., Roctavian for hemophilia A). Comparable to Kate as a rare disease gene therapy developer, though BioMarin operates at significantly larger scale across multiple therapeutic areas.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other neuromuscular disorders. Comparable to Kate in muscle-targeted AAV capsid approach and rare muscle disease focus.

TypeOthers
Description

Japanese pharmaceutical company that was Kate's exclusive licensee for KT430 (ASP2957) for XLMTM and the developer of AT132, whose liver toxicity issues Kate's MyoAAV capsid was designed to address. Relevant as Kate's primary commercial partner and a benchmark for muscle-directed AAV development.

TypeBroad incumbent
Description

Global pharmaceutical company with gene therapy capabilities including AAV-based treatments for neuromuscular diseases (e.g., Beqvez for hemophilia B). Comparable as a large-pharma acquirer/developer of gene therapy platforms.

TypeDirect peer
Description

Commercial-stage gene therapy leader for Duchenne muscular dystrophy and other neuromuscular diseases using AAV-based delivery. Directly comparable to Kate as a muscle-directed AAV gene therapy developer targeting rare neuromuscular indications.

TypeEmerging player
Description

Emerging gene therapy company developing novel AAV capsids for muscle and central nervous system diseases. Comparable to Kate as a capsid-engineering platform company targeting muscle tissue.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kate Therapeutics

Gene Therapy - Rare Neuromuscular & Cardiac Diseaseskatetherapeutics.com

Kate Therapeutics was a San Diego-based biotechnology company that developed next-generation gene therapies for muscle and heart diseases using its proprietary MyoAAV capsid platform; the company was acquired by Novartis in 2024 for approximately $1.1 billion.

What Kate Therapeutics does

Kate Therapeutics was a privately held biotechnology company headquartered in San Diego, California, that developed next-generation gene therapies targeting skeletal muscle and heart diseases. Founded circa 2020, the company emerged from stealth mode in June 2023 alongside a $51 million Series A financing led by Versant Ventures and Westlake Village BioPartners, with participation from OUP (Osage University Partners) and UF Innovate Ventures. It was subsequently acquired by Novartis in 2024 for approximately $1.1 billion.

The company's core technology centered on a proprietary MyoAAV capsid platform combined with novel gene therapy cargo technologies, enabling targeted delivery of therapeutic genes to muscle and cardiac tissues. The MyoAAV capsid was reported to achieve comparable or improved muscle targeting at approximately 100-fold lower doses than earlier gene therapy approaches (specifically AT132), directly addressing the liver toxicity issues that had derailed earlier neuromuscular gene therapy programs. The disclosed pipeline included KT430 for X-linked myotubular myopathy (XLMTM), which was exclusively licensed to Astellas Pharma and advanced as ASP2957 into the Phase I/II VALOR trial, plus preclinical programs targeting myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.

The business model was that of a research-stage biotech: Kate generated no product revenue and monetized through scientific publications, conference presence, and strategic licensing partnerships rather than direct commercialization. Following its acquisition, Kate's programs and expertise were integrated into Novartis's consolidated genetic medicine research operations in San Diego, joining prior acquisitions including AveXis and DTx Pharma. The founders included Sharif Tabebordbar (Chief Scientific Officer), Kevin Forrest (Chief Executive Officer), and Mark Fielden (SVP of Nonclinical Development), with Beth Seidenberg serving as Chair of the Board.

Kate Therapeutics firmographics

Firmographics
Name
Kate Therapeutics
Legal name
Kate Therapeutics Inc.
Website
https://katetherapeutics.com
Company type
Private
Founded year
2020
Operating status
Acquired
Headcount range
11–50 employees
Short description
Kate Therapeutics was a San Diego-based biotechnology company that developed next-generation gene therapies for muscle and heart diseases using its proprietary MyoAAV capsid platform; the company was acquired by Novartis in 2024 for approximately $1.1 billion.
Ownership category
akta.pro rank

Kate Therapeutics industry classification

Industry
Product category
Gene Therapy - Rare Neuromuscular & Cardiac Diseases
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy development
  • Muscle disease therapeutics
  • Cardiac disease treatments
  • Viral vector capsids
  • Rare disease biotech

Where Kate Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Kate Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels1 record

Kate Therapeutics product offering

Product offering

Core offering

Kate Therapeutics developed next-generation gene therapies for muscle and heart diseases, built on a proprietary capsid and cargo delivery platform. Its lead asset, KT430, targeted X-linked myotubular myopathy (XLMTM) and was licensed exclusively to Astellas Pharma (incorporated into ASP2957), while additional pipeline programs addressed myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. The company's MyoAAV capsid technology enabled targeted muscle delivery at approximately 100-fold lower doses than earlier gene therapy approaches, addressing liver toxicity concerns that had hindered prior programs.

Product overview

Kate Therapeutics was a gene therapy company focused on developing targeted delivery platforms for muscle and heart diseases. The company built its business around a novel capsid and cargo technology platform, including the proprietary MyoAAV capsid technology that enables improved muscle targeting. The pipeline included KT430 (licensed to Astellas for X-linked myotubular myopathy) and programs targeting myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. Kate Therapeutics was acquired by Novartis in 2024 for approximately $1.1 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novel Capsid and Cargo Technology Platform

Quantifiable outcome

  • MyoAAV3.8 demonstrated approximately 100-fold lower dosing requirement than AT132 while maintaining improved muscle targeting in preclinical studies

Companies that use Kate Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Kate Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Kate Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Novartis AGflagshipStrategic or Co-development Partner · 1 January 2024Novartis acquired Kate Therapeutics in 2024 for $1.1 billion as part of its strategy to build a leading gene therapy capability. Kate's programs and expertise in neuromuscular diseases were integrated into Novartis's consolidated genetic medicine research operations in San Diego, combining with AveXis, DTx Pharma, and other acquisitions under Executive Director Bryan Laffitte.
  • Astellas Pharma Inc.coreOEM/ Whitelabel/ Licensing Partner · 8 June 2023Kate Therapeutics granted Astellas Pharma Inc. an exclusive license to develop KT430 (later incorporated into ASP2957) for X-linked myotubular myopathy (XLMTM). Astellas advanced this therapy into Phase I/II VALOR trial using the MyoAAV capsid technology from Kate. The partnership represents a significant licensing arrangement for muscle disease gene therapies.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Kate Therapeutics competitors and assessment

Company assessment

Direct peers

  • uniQure: Gene therapy company with AAV-based platform and clinical programs in rare neuromuscular and metabolic diseases. Comparable as a developer of AAV-delivered gene therapies for rare genetic disorders.
  • Regenxbio: Clinical-stage gene therapy company with proprietary AAV capsid platform (NAV Technology) used across multiple partners for neuromuscular and rare disease indications. Comparable to Kate's MyoAAV capsid platform approach.
  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other neuromuscular disorders. Comparable to Kate in muscle-targeted AAV capsid approach and rare muscle disease focus.
  • Sarepta Therapeutics: Commercial-stage gene therapy leader for Duchenne muscular dystrophy and other neuromuscular diseases using AAV-based delivery. Directly comparable to Kate as a muscle-directed AAV gene therapy developer targeting rare neuromuscular indications.

Emerging players

  • Lexeo Therapeutics: Clinical-stage AAV gene therapy company focused on cardiac and neuromuscular diseases. Comparable to Kate in combining cardiac and muscle targets with AAV delivery technology.
  • Tenaya Therapeutics: Clinical-stage gene therapy company developing treatments for genetic heart disease, including cardiomyopathy. Comparable to Kate's cardiac gene therapy component and rare disease focus.
  • Affinia Therapeutics: Emerging gene therapy company developing novel AAV capsids for muscle and central nervous system diseases. Comparable to Kate as a capsid-engineering platform company targeting muscle tissue.

Broad incumbents

  • BioMarin Pharmaceutical: Large rare disease biopharmaceutical company developing AAV gene therapies (e.g., Roctavian for hemophilia A). Comparable to Kate as a rare disease gene therapy developer, though BioMarin operates at significantly larger scale across multiple therapeutic areas.
  • Pfizer: Global pharmaceutical company with gene therapy capabilities including AAV-based treatments for neuromuscular diseases (e.g., Beqvez for hemophilia B). Comparable as a large-pharma acquirer/developer of gene therapy platforms.

Others

  • Astellas Pharma: Japanese pharmaceutical company that was Kate's exclusive licensee for KT430 (ASP2957) for XLMTM and the developer of AT132, whose liver toxicity issues Kate's MyoAAV capsid was designed to address. Relevant as Kate's primary commercial partner and a benchmark for muscle-directed AAV development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Kate Therapeutics social profiles

Digital presence

Kate Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kate Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Kate Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kate Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kate Therapeutics

What does Kate Therapeutics do?

Kate Therapeutics developed next-generation gene therapies for muscle and heart diseases, built on a proprietary capsid and cargo delivery platform. Its lead asset, KT430, targeted X-linked myotubular myopathy (XLMTM) and was licensed exclusively to Astellas Pharma (incorporated into ASP2957), while additional pipeline programs addressed myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. The company's MyoAAV capsid technology enabled targeted muscle delivery at approximately 100-fold lower doses than earlier gene therapy approaches, addressing liver toxicity concerns that had hindered prior programs.

Is Kate Therapeutics a public or private company?

Kate Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Kate Therapeutics founded?

Kate Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Kate Therapeutics based?

Kate Therapeutics is headquartered in San Diego, United States, in the North America region.

Who are Kate Therapeutics's main competitors?

Direct peers on record are uniQure, Regenxbio, Solid Biosciences and Sarepta Therapeutics. Emerging players are Lexeo Therapeutics, Tenaya Therapeutics and Affinia Therapeutics. Broad incumbents are BioMarin Pharmaceutical and Pfizer. Astellas Pharma is listed as an others.

Does Kate Therapeutics have an API?

No public API is recorded for Kate Therapeutics.

What industry is Kate Therapeutics in?

Kate Therapeutics's product category is Gene Therapy - Rare Neuromuscular & Cardiac Diseases. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechAstellas thins early pipeline, swaps out struggling rare disease gene therapyAstellas Pharma has halted development of its gene therapy AT132 for X-linked myotubular myopathy and terminated two phase 1 candidates, ASP5502 and ASP1570, resulting in a 16.4 billion yen (~$103 million) impairment charge. The AT132 therapy, originally acquired through Astellas' $3 billion purchase of Audentes Therapeutics in 2019, was linked to four patient deaths from liver failure that led to an FDA clinical hold. The company is shifting focus to a new gene therapy, ASP2957, licensed from Kate Therapeutics in 2023, which demonstrated improved muscle targeting in preclinical studies at approximately 100-fold lower doses than AT132.NovartisWhat's next in Neuroscience drug discoveryNovartis has consolidated its genetic medicine research in San Diego by combining its gene therapy and xRNA teams under Executive Director Bryan Laffitte to accelerate development of therapies for neuromuscular and neurodegenerative diseases. The unified team was formed through acquisitions including AveXis (2018), DTx Pharma (2023), and Kate Therapeutics (2024), bringing in programs and expertise targeting the same indications. The team is developing new delivery technologies including capsids targeting muscle, heart, and CNS tissues, and exploring blood-brain barrier crossing mechanisms for siRNA delivery to treat neurological conditions.GenengnewsAstellas Takes Aim at XLMTM Again, Now with MyoAAV Capsid-Based Gene TherapyAstellas Gene Therapies is advancing ASP2957 (MyoAAV3.8-MHCK7-hMTM1), a new gene therapy for X-linked Myotubular Myopathy (XLMTM), into a Phase I/II VALOR trial following four patient deaths in the earlier ASPIRO trial with AT132. The new therapy uses a MyoAAV capsid developed by Kate Therapeutics (acquired by Novartis in 2024) that allows for significantly lower dosing to address liver toxicity concerns identified in the prior trial. Astellas expects to dose its first patient in the VALOR trial by the end of its fiscal year (March 31), while also continuing partnerships with Sangamo Therapeutics and Dyno Therapeutics on next-generation capsid development.openPR.comGene Therapy Market Dynamics and Competitive Landscape 2025-2032The global gene therapy market is projected to grow from USD 10.03 billion in 2024 to USD 32.89 billion by 2032, a CAGR of 16%. Growth is driven by rising genetic disorders and CRISPR-Cas9 advancements, with Novartis acquiring Kate Therapeutics for USD 1.1 billion in November 2024.YahooNovartis acquires Kate Therapeutics to advance gene therapiesNovartis acquired San Diego-based Kate Therapeutics for $1.1bn, adding preclinical gene therapies for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1. The deal includes upfront cash and milestone-contingent payments, and Kate's DELIVER platform uses capsid libraries and machine learning to target specific tissues.SdbnNovartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy – San Diego Biotechnology NetworkNovartis acquired Kate Therapeutics for up to $1.1 billion, expanding its presence in neuroscience drug development and gene therapy. Kate's DELIVER platform uses AAV capsid evolution to target neuromuscular diseases while reducing liver off-target effects.SecSEC FORM DThe SEC filing reports that Kate Therapeutics Inc. has submitted a Form D for an exempt offering of securities totaling $35 million. The offering, which does not allow for continuous sales, has successfully sold the full amount previously and is not associated with a business combination transaction.SecSEC FORM DKate Therapeutics Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing discloses a total offering amount of $16,000,000 USD for equity securities, with the first sale dated February 5, 2021.SecSEC FORM DKate Therapeutics Inc. filed a Form D with the SEC for an exempt securities offering under Rule 506(b), with total proceeds reaching approximately $21.8 million out of a $23.4 million target. The filing, signed by CEO Kevin Forrest in August 2024, indicates that eight investors have participated in the equity offering.